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A population-based analysis of endovascular versus
open thoracic aortic aneurysm repair
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Himanshu J. Patel, MD,c and Gilbert R. Upchurch Jr, MD,d Ann Arbor, Mich
Objective:The perioperative outcomes of open surgical and endovascular repair of intact thoracic aortic aneurysms (TAAs)
during the last 3 months of 2005 were compared using a national administrative database.
Methods: The Nationwide Inpatient Sample was used to identify patients undergoing open aneurysm repair (OAR) or
endovascular TAA repair (TEVAR) from October 1 to December 31, 2005. Patient demographic data, length of stay,
hospital charges, patient disposition, and mortality were examined. Where appropriate, univariate tests of association
used the 2 test, and multiple logistic regression analysis was used to determine predictors of in-hospital mortality,
complications, and discharge status.
Results: A total of 1030 patients underwent open TAA repair and 267 underwent TEVAR. There was no significant
difference in mortality between OAR and TEVAR (adjusted odds ratio [OR], 1.2; 95% confidence interval [CI],
0.73-2.12), although OAR patients were more likely to have cardiac, respiratory, and hemorrhagic complications.
Patients undergoing TEVAR were more likely to be discharged to home (adjusted OR, 6.37; 95% CI, 2.93-13.70) and
had a decreased length of stay (5.7 days vs 9.9 days; P  .0015). The differences in hospital charges and costs were not
significant.
Conclusion: Although further study is warranted, this study of a national sample suggests that endovascular TAA repair
is safe in the short-term, associated with fewer cardiac, respiratory, and hemorrhagic complications, and requires a shorter
hospital stay. ( J Vasc Surg 2009;49:1112-6.)An open surgical approach to thoracic aortic aneurysm
(TAA) repair has been the method of treatment for 50
years. Open aneurysm repair (OAR) is associated with
significant complications, however, including intraopera-
tive and postoperative myocardial infarction, renal insuffi-
ciency, hemorrhage, postoperative pneumonia, lower ex-
tremity ischemia, stroke, and paralysis. These risks are
compounded because aneurysm patients frequently have
multiple cardiovascular comorbidities, protracted hospital
stays, and poor long-term survival.1 Despite this, these risks
are frequently outweighed by the threat of aneurysm rup-
ture, estimated to be 50% to 75% for large, untreated
aneurysms, and its incumbent high mortality rate.2-4
The last 20 years has witnessed the rapid development
of a number of catheter-based approaches for the treatment
of vascular pathologies since Parodi first established the
feasibility of endovascular stent grafting.5 In the mid-
1990s, the endovascular paradigm was first applied to an-
eurysms of the thoracic aorta.6,7 Short-term results appear
promising, but there remains a dearth of evidence on the
success of this approach, in no small part due to the
relatively rare occurrence of TAA compared with abdomi-
nal aortic aneurysm (AAA). TAA is estimated to occur in
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11126/100,000 person-years, compared with 36.5/100,000
person-years for AAA.4,8 To date, no prospective, random-
ized trial has compared the two approaches, and the current
published reports are plagued with significant limitations.9
Single-institution studies often display sampling bias and
the effects of institutional learning curves. Case series are
frequently weakened by small patient sample sizes and
heterogeneous patient populations.
In late 2005, an International Classification and Diag-
nosis, Ninth Revision (ICD-9), procedure code unique to
endovascular thoracic aortic aneurysm repair (TEVAR) was
introduced.10 This allows for an analysis of data comparing
OAR and TEVAR that provides a “snapshot” of the current
state of practice in the United States (US). A literature
search reveals that this is the first study comparingOAR and
TEVAR patient outcomes from a large, unselected sam-
pling that represents nearly the entire scope of unruptured
TAA repairs in the country.
METHODS
All data were abstracted from the Nationwide Inpatient
Sample (NIS)11 fromOctober 1, 2005, throughDecember
31, 2005. The NIS, the largest all-payer inpatient care
database, is sponsored by the Agency for Healthcare Re-
search and Quality12 and contains data from 8 million
hospital discharges annually from 1054 hospitals in 37
states, representing 90% of all US hospital discharges. The
database contains patient and hospital demographic data,
ICD-9 diagnosis and procedure codes, mortality informa-
tion, and hospital charges.
Patients with an ICD-9 primary diagnosis code for
TAA without mention of rupture (441.2) and with a pri-
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graft in the thoracic aorta or resection of a vessel with
replacement, specifically any thoracic vessel involvement
(39.73 and 38.45, respectively) were selected for analysis.
Exclusion criteria included age 50 years, concurrent
ICD-9 procedure codes for both OAR and TEVAR, and
ICD-9 diagnosis codes for congenital anomalies such as
gonadal dysgenesis, Marfan syndrome, and Turner syn-
drome, as well as the diagnosis of polyarteritis nodosa
(758.6, 759.82, 446). Patients with abdominal or thoraco-
abdominal aneurysm diagnosis codes (441.1, 441.5,
441.4, 441.0, 441.6, 441.7) were excluded, as were those
with procedure codes for the repair of these pathologies
(39.71, 38.44).
Outcomes assessed included in-hospital mortality,
postoperative complications, length of stay, hospital
charges, hospital costs, patient disposition after discharge,
and patient demographics such as age, gender, race, and
number of cardiovascular comorbidities. The ICD-9 cod-
ing system has specific codes for complications resulting
from a procedure, and these were used to determine the
complication rates. The number of comorbidities was de-
termined by the presence of ICD-9 diagnosis codes for
diabetes mellitus, hypertension, preoperative renal insuffi-
ciency, chronic obstructive pulmonary disease, ischemic
heart disease, cerebrovascular occlusive disease, and periph-
Table I. Demographic and cardiovascular comorbidity da
repair
Variable Total
Patients, No. (%) 1030 (100)















Renal insufficiencyc 150 (14.6)
COPDd 204 (19.8)
Ischemic heart diseasee 397 (38.5)
CVODf 91 (8.8)
PADg 75 (7.3)
COPD, Chronic obstructive pulmonary disease; CVOD, cerebrovascular o
TEVAR, thoracic endovascular aneurysm repair.
aBased on ICD-9 codes 250.0-250.9.
bBased on ICD-9 codes 401.0-405.9.
cBased on ICD-9 codes 584.0-586.0.
dBased on ICD-9 codes 490.0-496.0.
eBased on ICD-9 codes 410.0-414.9.
fBased on ICD-9 codes 430.0-438.0.
gBased on ICD-9 codes 440.0-440.9, 443.0-443.9.eral arterial disease.Statistical analysis was performed using SAS 9.1 soft-
ware (SAS Institute, Cary, NC). Descriptive statistics for
baseline patient characteristics and in-hospital mortality
were obtained. Where appropriate, univariate tests of asso-
ciation used the 2 test, and multiple logistic regression
analyses were used to determine predictors of in-hospital
mortality, complications, and discharge status. Odds ratios
(OR) and 95% confidence intervals (CI) were calculated.
Values of P  .05 were considered statistically significant.
RESULTS
During the last quarter of 2005, 1030 intact, unrup-
tured TAAs were repaired (Table 1). Of those, 267 (26%)
were repaired by TEVAR, and the remaining 763 (74%)
were repaired by OAR.
The average ages were 66 years for OAR patients and
nearly 70 years for TEVAR (P  .01). Data on race were
unavailable for 253 patients (24.6%). Of the remaining
patients, almost 15% were nonwhite, and 43% of these
underwent TEVAR compared with 19% of white patients
(P  .0001). Women comprised one-third of the sample
size (n  341) and were as likely as men to undergo
TEVAR (24% vs 27%; P  .35).
TEVAR patients tended to have a higher burden of
cardiovascular comorbidities (P  .0001). Although
TEVAR and OAR patients were similar in their rates of
r open versus endovascular thoracic aortic aneurysm
OAR TEVAR P
763 (74.0) 267 (26.0)
6.1  21.3 69.9  20.9 .01
504 (66.1) 185 (69.2)
259 (33.9) 82 (30.8) .35
533 (89.0) 128 (71.8)
66 (11.0) 50 (28.2) .0001
407 (53.3) 83 (31.2)
330 (43.3) 153 (57.3)
26 (3.4) 31 (11.6) .0001
84 (11.0) 20 (7.6) .12
490 (64.3) 204 (76.2) .0004
97 (12.7) 53 (20.0) .0036
138 (18.1) 66 (24.8) .02
282 (36.9) 115 (43.1) .07
41 (5.3) 50 (18.8) .0001
25 (3.3) 50 (18.7) .0001
ve disease; OAR, open aneurysm repair; PAD, peripheral arterial disease;ta fo
6
cclusidiabetes mellitus (P .12) and ischemic heart disease (P
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have hypertension, renal insufficiency, chronic obstructive
pulmonary disease, cerebrovascular occlusive disease, and
peripheral artery disease (Table 1).
In-hospital mortality did not differ between the two
repair approaches (Table II): OAR patients had a 6.4%
mortality rate compared with 7.7% for TEVAR patients
(P .49). OAR patients had a higher overall complication
rate (33% vs 20%; P  .0001). The two approaches were
equivalent in their rates of iatrogenic cerebrovascular acci-
dent; however, hematoma development, postoperative in-
fections, and cardiac, respiratory, and hemorrhagic compli-
cations were more likely to develop in OAR patients (Table
III).
On average, TEVAR patients had hospital stays that
were approximately half as long as OAR patients (P 
.0015) and were more likely to be discharged to home
rather than to an extended-care facility (P  .0001; Fig).
Most TEVAR patients are discharged from the hospital
within the first few days of their procedure, and a signifi-
cantly higher number of OAR patients had prolonged
hospitalizations (10 days) than did TEVAR patients.
TAA repair had an average hospital charge to the pa-
tient or insurer of $119,932 and an average cost to the
hospital of $50,285, with no significant difference between
the two approaches (data not shown). A subgroup analysis
of patients who were free of complications found that the
TEVAR approach was associated with a $10,000 reduction
in cost (P  .0331), but no difference in hospital charges.
Multivariate analysis used the type of repair, age, gen-
der, and the number of comorbidities to predict death, the
development of a complication, and discharge to home
(Table IV). OAR and an increased comorbidity burden
were significant predictors of death. The type of repair and
age predicted the development of a complication, and the
repair type, age, gender, and comorbidity burden all pre-
dicted discharge to home.
DISCUSSION
Although our study demonstrated no difference in
Table II. Clinical outcomes after open vs endovascular
thoracic aortic aneurysm repair
Variable OAR TEVAR P
Total patients, No. (%) 763 (74.0) 267 (26.0)
Death, No. (%) 49 (6.4) 21 (7.7) .49
Complication, No. (%)
Any 253 (33.1) 55 (20.4) .0001
Cardiac 144 (18.9) 15 (5.7) .0001
Length of stay, d
Median  SD 9.9  20.3 5.7  10.2 .0015
Median 7 5 .0011
Disposition, No. (%)
Home 601 (78.8) 242 (90.3)
Institution 112 (14.7) 5 (2.0) .0001
OAR, Open aneurysm repair; SD, standard deviation; TEVAR, thoracic
endovascular aneurysm repair.mortality rates between TEVAR (95%CI, 5.2%-11.7%) andOAR (95% CI, 4.9%-8.4%), TEVAR was associated with a
significantly shorter hospital stay, fewer cardiac, respiratory,
and hemorrhagic complications, and a higher likelihood of
discharge to home rather than an extended-care facility.
Multivariate analysis revealed that women are less likely
to be discharged to home than men. Overall, women
undergoing TAA repair were older than their male coun-
terparts (P  .0270), and this was generally true when
broken down by repair type and the number of comorbidi-
ties present. No women with four or more comorbidities
underwent TEVAR. Women undergoing TAA repair
tended to be older and sicker, which may explain why
female gender predicts discharge to an extended-care facil-
ity rather than to home.
Based on our data, OAR is currently performed approx-
imately three times as often as TEVAR. If the experience
with AAA is mirrored, it is entirely likely that the propor-
tion of TAA repairs performed with an endovascular ap-
proach will increase. Stent grafts are designed and simulation-
tested to be durable for 10 years, and in the coming years,
more evidence will become available about the in vivo
longevity of these grafts.9 If the data are favorable, many
more patients, particularly younger patients, will become
candidates for TEVAR. As the technology proliferates and
the collective clinical experience with TEVAR increases on
an individual practitioner and an institutional level, the
mortality rate associated with endovascular repair for TAAs
may decrease just as it has for endovascular AAA repair.13,14
Our study demonstrated equivalent in-hospital costs
and charges for the two types of repair. Although this
information is useful in informing health care economists,
policy decisions must be based on in-hospital as well as
long-term financial data. That TEVAR patients are more
often discharged to home rather than to an extended-care
facility may favor this approach in the short-term, although
this information must be tempered by the fact that many
well-recognized complications of EVAR—namely en-
doleak, stent migration, and stent fracture—are known to
occur more frequently after hospital discharge. In addition,
TEVAR patients currently require life-long computed to-
mography surveillance, a cost that is not captured by the
NIS. Further study comparing the late costs of both ap-
proaches using different data sources is needed.
Analysis of data for those patients who were free of
complications revealed that the length of stay was short-
ened by approximately 1 day for both types of repair and
costs and charges were decreased. The decrease in costs
favored TEVAR.
Analysis of patient demographics reveals that this is one
of the few examples in medicine of patients who belong to
a minority racial group being more likely to receive the
cutting edge care (ie, TEVAR). Prima facie, it may suggest
that nonwhite patients are recipients of better, more tech-
nologically advanced care. A more likely explanation, how-
ever, is that minority patients tend to come to medical
attention much later than white patients and with more
cardiovascular comorbidities, making them poorer candi-
dates for OAR. Certainly, this explanation would be more
JOURNAL OF VASCULAR SURGERY
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ities in cardiovascular health care.15-17
This investigation does present limitations associated
with studies that use large administrative databases. Owing
to the nature of the NIS, only in-hospital events, including
mortality, can be captured. Because hospital admissions are
not linked, readmissions are counted as separate events and
cannot be linked to the original hospitalization. Accord-
ingly, theNIS is not an appropriate data source for assessing
late complications associated with TEVAR.
Furthermore, limited clinical information is available,
making it impossible to garner more specific details such as
aneurysm size or morphology. It is also not possible to
evaluate all of the clinically important outcomes of TAA
repair with the NIS, including postoperative paraplegia,
which is a well-known and feared complication of TAA
repair. The complication code for iatrogenic cerebrovascu-
lar accident refers specifically to ischemic or hemorrhagic
stroke complicating a procedure. Although the code may
include postprocedural paralysis, it is secondary to cerebral
damage as the mechanism of injury, rather than spinal cord
injury, which is a major concern in the repair of TAA but,
Table III. Postoperative complications after open versus e
Variable OAR
Iatrogenic CVAa 0.034




Complication during a procedure
Hemorrhagee 0.064
Hematomaf 0.077
Other postoperative infectiong 0.014
CI, confidence interval; CVA, cerebrovascular accident; OAR, open aneury
aBased on ICD-9 code 997.02.
bBased on ICD-9 code 997.1.
cBased on ICD-9 code 997.3.
dBased on ICD-9 code 997.5.
eBased on ICD-9 code 998.11.
fBased on ICD-9 code 998.1.
gBased on ICD-9 code 998.5, 998.59.
Fig 1. Inpatient length of stay for open (dark bars) and endovas-
cular (gray bars) thoracic aortic aneurysm repair.regrettably, cannot be assessed using the NIS database.The limited granularity of the database precludes its use
in ascertaining more detailed information about the exact
surgical methods used. Certain techniques for open surgi-
cal repair have become outmoded, but the database does
not distinguish those cases in which they are used from the
ones in which the most up-to-date, preferred surgical
vascular thoracic aortic aneurysm repair








air; OR, odds ratio; TEVAR, thoracic endovascular aneurysm repair.
Table IV. Multivariate analysis of independent
predictors of adverse outcomes
Outcome OR 95% CI P
Death
Repair type (OAR vs TEVAR) 3.5 1.2-10.4 .03
Age (vs 50-64 years)
65-79 2.4 0.4-14.1 .53
80 1.6 0.2-12.3
Sex (male vs female) 0.8 0.4-1.9 .68
Comorbidities (vs 0-1)
2-3 1.4 0.6-3.3 .0001
4-5 14.1 4.9-40.7
Complication
Repair type (OAR vs TEVAR) 1.5 1.0-2.3 .04
Age (vs 50-64 years)
65-79 2.7 1.6-4.7 .001
80 2.9 1.4-6.0
Sex (male vs female) 1.0 0.7-1.4 .92
Comorbidities (vs 0-1)
2-3 1.0 0.7-1.4 .18
4-5 0.4 0.2-1.1
Discharge to home
Repair type (OAR vs TEVAR) 0.1 0.1-0.3 .0001
Age (vs 50-64 years)
65-79 0.4 0.1-1.1 .04
80 0.2 0.1-0.7
Sex (male vs female) 3.4 2.1-5.5 .0001
Comorbidities (vs 0-1)
2-3 0.4 0.3-0.7 .0001
4-5 0.0 0.0-0.1
CI, Confidence interval; EVAR, endovascular aneurysm repair; OAR, open
aneurysm repair; OR, odds ratio; TEVAR, thoracic endovascular aneurysm
repair.ndo
sm repmethods are used. This analysis includes all of those cases.
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repairs fitting the inclusion criteria were included in this
study, irrespective of surgeon and hospital volume. The
literature does suggest that increased hospital volume—and
especially surgeon volume—are important determinants of
patient outcomes, particularly in major procedures such as
TAA repair.18,19
Only in-hospital events were captured, so it is possible
that the TEVAR mortality rate is underestimated because
these patients are released from the hospital more quickly
than OAR patients; however, the equivalent mortality rates
are consistent with single-institution series comparing the
two approaches.20,21 On the other hand, OAR patients are
more likely to be discharged to an extended-care facility.
Deaths that occur at these secondary facilities are not
captured in the NIS database, which may cause the OAR
mortality rate to be underestimated as well. Studies of
midterm follow-up for TEVAR show that the real concern
for death lies in the immediate perioperative period before
hospital discharge,22-24 suggesting that our mortality rate
accurately captures the bulk of repair-related deaths.
CONCLUSIONS
This study demonstrates that endovascular repair is
equivalent to open surgical repair for TAA repair in terms of
in-hospital mortality, and is favorable in the development
of cardiac, respiratory, and hemorrhagic complications,
hospital length of stay, and discharge to home. Additional
long-term study of the clinical and economic outcomes, as
well as select immediate postoperative outcomes, such as
paraplegia, between the two approaches is warranted.
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